Seek Returns

RPRX vs. VTRS: Royalty Pharma vs. Viatris Stock Comparison

How do Royalty Pharma (RPRX) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Royalty Pharma (RPRX) and Viatris (VTRS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Viatris (VTRS) has more than two decades of public-market history since March 17, 1980, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Company profile comparison for Royalty Pharma (RPRX) and Viatris (VTRS)
Profile ItemRPRXVTRS
NameRoyalty Pharma plc Class A Ordinary SharesViatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization38.70 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 16, 2020March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

RPRX
VTRS
GSPC
Loading price history…
Royalty Pharma (RPRX) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Royalty Pharma (RPRX) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Royalty Pharma (RPRX) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Royalty Pharma (RPRX) and Viatris (VTRS)
MetricRPRXVTRS
Total Return (1Y)81.08%108.98%
Total Return (3Y, Annualized)39.21%36.75%
Total Return (5Y, Annualized)14.22%11.59%

Risk Profile

Drawdown History

RPRX
VTRS
GSPC
Loading price history…
Royalty Pharma (RPRX) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Royalty Pharma (RPRX) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Royalty Pharma (RPRX) and Viatris (VTRS)
MetricRPRXVTRS
Volatility (1Y, Annualized)22.05%32.53%
Beta (5Y)0.360.86
Max Drawdown (5Y)-41.98%-45.69%
Avg. Volume (3M)3.10M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RPRX and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Royalty Pharma (RPRX) and Viatris (VTRS)
MetricRPRXVTRS
Sharpe Ratio (1Y)3.483.22
Sortino Ratio (1Y)5.725.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Royalty Pharma (RPRX) reports 12.09%, ranking against industry peers normally.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.09%

Max
109.18%
RPRX
12.09%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Royalty Pharma (RPRX) reports 25.70%, ranking against industry peers normally.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.70%

RPRX
25.70%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Royalty Pharma (RPRX) at 81.32% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.32%

Max
83.12%
RPRX
81.32%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Royalty Pharma (RPRX) and Viatris (VTRS)
MetricRPRXVTRS
ROE (TTM)12.09%-4.21%
ROA (TTM)5.43%2.91%
Net Margin (TTM)25.70%-4.13%
Operating Margin (TTM)81.32%13.85%
Gross Margin (TTM)99.79%41.13%

Growth

Revenue Growth

Royalty Pharma (RPRX) at 5.06% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Royalty Pharma (RPRX) reports EPS growth of 23.09%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Royalty Pharma (RPRX) and Viatris (VTRS)
MetricRPRXVTRS
Revenue Growth (YoY)5.06%-2.98%
Revenue Growth (3Y CAGR)2.06%-4.20%
EPS Growth (YoY)23.09%--
EPS Growth (3Y CAGR)161.10%--

Financial Strength

Current Ratio (MRQ)

Both Royalty Pharma (RPRX) at 1.29 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RPRX
1.29
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Royalty Pharma (RPRX) at 0.88 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max
1.42
RPRX
0.88
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Royalty Pharma (RPRX) and Viatris (VTRS)
MetricRPRXVTRS
Current Ratio (MRQ)1.291.55
Debt / Equity (MRQ)0.880.99
Net Debt / EBITDA4.762.64

Dividends

Dividend Yield (TTM)

Both Royalty Pharma (RPRX) at 1.37% and Viatris (VTRS) at 2.53% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.37%

RPRX
1.37%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Royalty Pharma (RPRX) reports 60.46%, ranking against industry peers normally.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.46%

RPRX
60.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Royalty Pharma (RPRX) and Viatris (VTRS)
MetricRPRXVTRS
Dividend Yield (TTM)1.37%2.53%
Dividend Payout Ratio (TTM)60.46%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Royalty Pharma (RPRX) trades at 43.99 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.99

Max
85.34
RPRX
43.99
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; RPRX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Royalty Pharma (RPRX) at 14.79 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.79

Max
58.18
Q3
25.77
RPRX
14.79
Median
7.30
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Royalty Pharma (RPRX) at 4.39 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.39

Max
13.53
Q3
6.54
RPRX
4.39
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Royalty Pharma (RPRX) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Royalty Pharma (RPRX) and Viatris (VTRS)
MetricRPRXVTRS
P/E Ratio (TTM)43.99--
P/S Ratio (TTM)14.791.55
P/B Ratio (MRQ)4.391.67
Free Cash Flow Yield (TTM)-1.16%13.84%